偏头痛治疗新药atogepant的药理作用与临床评价

Pharmacological and clinical evaluation of atogepant in the treatment of migraine

Atogepant是一种口服的小分子降钙素基因相关肽受体拮抗药。2021年9月,atogepant在美国被批准用于成人发作性偏头痛的预防性治疗。Atogepant每日给药1次,能显著降低受试者的平均每月偏头痛天数,且耐受性好。最常见的药物不良反应是便秘和恶心,无明显肝不良反应和药物相互作用。本文从药理作用、药代动力学、临床评价、安全性、相互作用等方面对atogepant进行综述。

Atogepant is an orally administered,small-molecule,calcitonin gene-related peptide receptor antagonist.In September 2021,atogepant was approved in the USA for the preventive treatment of episodic migraine in adults.Atogepant,administered once daily,significantly reduced the mean number of migraine days per month for migraine sufferers.The most common adverse reactions were constipation and nausea,without significant hepatic adverse reactions or drug interactions.The pharmacology,pharmacokinetics,clinical evaluation,safety,as well as drug interactions of atogepant are reviewed in this article.